Study guide
Diabetic microangiopathy and NPDR classification
European Board of Ophthalmology Diploma EBOD
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: EBOD Examination, Applications and Regulations
EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals
2 Chapter 2: Physical Optics, Photometry and Lenses
Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid
3 Chapter 3: Instrument Optics, Aberrations and Laser Physics
Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT
4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing
Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses
5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation
Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics
6 Chapter 6: Extraocular Anatomy and Motor Physiology
Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys
7 Chapter 7: Binocular Vision and Amblyopia
Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment
8 Chapter 8: Childhood Assessment and Strabismus Testing
Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts
9 Chapter 9: Esotropia, Exotropia and Vertical Deviations
Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew
10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery
Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles
11 Chapter 11: ROP and Paediatric Ocular Disease
Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding
12 Chapter 12: Ocular Surface Anatomy and Infection
Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis
13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation
Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis
14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies
Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies
15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure
Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency
16 Chapter 16: Surface Reconstruction and Keratoplasty
Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems
17 Chapter 17: Lens Development, Cataract Assessment and Biometry
Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry
18 Chapter 18: IOL Planning and Phacoemulsification
Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques
19 Chapter 19: Cataract Anaesthesia and Surgical Complications
Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO
20 Chapter 20: Corneal and Intraocular Refractive Surgery
Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange
21 Chapter 21: Presbyopia Procedures and Surface Therapeutics
Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin
22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy
Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation
23 Chapter 23: Angle, Disc and Visual-Field Assessment
Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry
24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms
Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure
25 Chapter 25: POAG, Angle Closure and Pigmentary Disease
POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma
26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment
Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers
27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion
Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions
28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy
Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis
29 Chapter 29: Inherited Retina and Electrophysiology
Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina
30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid
AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum
31 Chapter 31: Retinal Breaks and Detachment Repair
PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling
32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma
Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment
33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation
SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation
34 Chapter 34: Infectious Uveitis and Endophthalmitis
Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment
35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy
Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison
36 Chapter 36: Papilloedema, IIH and Afferent Localisation
Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization
37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology
Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies
38 Chapter 38: Central Motor Control and Cranial Nerve Palsies
Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus
39 Chapter 39: Myasthenia and Ocular Myopathy
Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome
40 Chapter 40: Pupillary Pathways and Anisocoria
Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials
41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment
Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation
42 Chapter 42: Lid Repair and Lacrimal Drainage
Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR
43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours
Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma
44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease
Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling
45 Chapter 45: Ocular Trauma and Vascular Systemic Disease
Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease
46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology
Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects
47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations
Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal
Diabetic microangiopathy and NPDR classification
Key Takeaways Explain This Topic AI
Hyperglycaemia damages the retinal neurovascular unit through several interacting metabolic and inflammatory pathways.
Microaneurysms, haemorrhages, venous beading and IRMA help classify nonproliferative severity.
The 4–2–1 rule is a defined grading framework rather than proof of identical progression in every patient.
Last updated: October 2026
Pathophysiology of Diabetic Microangiopathy
Diabetic retinopathy (DR) is the leading cause of preventable, moderate-to-severe visual impairment in the working-age population across European and industrialized nations. The microvascular sequelae of diabetes mellitus reflect cumulative cellular damage resulting from chronic, uncontrolled hyperglycaemia. Retinal capillary beds are uniquely vulnerable to metabolic insult due to their exceptionally high metabolic activity, tight autoregulatory demands, and dependence on a specialized neurovascular unit.
The Biochemical Cascades of Hyperglycaemic Damage
Intracellular hyperglycaemia within retinal capillary endothelial cells, pericytes, and neuroglial Müller cells initiates four major interconnected metabolic derangements:
The Polyol (Sorbitol) Pathway: Under physiological normoglycaemic conditions, glucose is metabolized via hexokinase into glucose-6-phosphate. In sustained hyperglycaemia, hexokinase becomes saturated, shunting excess intracellular glucose into the polyol pathway. The enzyme aldose reductase reduces glucose to sorbitol , consuming nicotinamide adenine dinucleotide phosphate ( NADPH \text{NADPH} NADPH ) as a cofactor: Glucose + NADPH + H + → Aldose Reductase Sorbitol + NADP + \text{Glucose} + \text{NADPH} + \text{H}^+ \xrightarrow{\text{Aldose Reductase}} \text{Sorbitol} + \text{NADP}^+ Glucose + NADPH + H + Aldose Reductase Sorbitol + NADP + Sorbitol dehydrogenase subsequently oxidizes sorbitol to fructose, reducing NAD + \text{NAD}^+ NAD + to NADH \text{NADH} NADH . Because sorbitol is a polar, impermeant polyol, it accumulates intracellularly, generating hyperosmotic stress and cellular swelling. Furthermore, the massive consumption of NADPH \text{NADPH} NADPH by aldose reductase depletes the critical cofactor required by glutathione reductase to regenerate reduced glutathione ( GSH \text{GSH} GSH ). The resulting failure of antioxidant scavenging triggers severe intracellular oxidative stress and reactive oxygen species (ROS) accumulation.
Advanced Glycation End-Products (AGEs): Excess ambient glucose non-enzymatically reacts with free amino groups on intra- and extracellular proteins, lipids, and nucleic acids (the Maillard reaction), forming irreversible advanced glycation end-products (AGEs) . Circulating and interstitial AGEs bind their cell-surface receptor, RAGE , on endothelial cells and pericytes. Receptor activation triggers downstream NF- κ B \text{NF-}\kappa\text{B} NF- κ B translocation, upregulating pro-inflammatory cytokines (tumour necrosis factor-alpha [ TNF- α \text{TNF-}\alpha TNF- α ], interleukin-6 [ IL-6 \text{IL-6} IL-6 ]), endothelin-1, and vascular cell adhesion molecule-1 ( VCAM-1 \text{VCAM-1} VCAM-1 ), promoting chronic leukostasis.
Protein Kinase C (PKC) Activation: De novo synthesis of diacylglycerol ( DAG \text{DAG} DAG ) from glycolytic intermediates activates classical and novel isoforms of Protein Kinase C , primarily PKC- β \text{PKC-}\beta PKC- β and PKC- δ \text{PKC-}\delta PKC- δ . PKC activation induces endothelial nitric oxide synthase ( eNOS \text{eNOS} eNOS ) uncoupling, enhances microvascular permeability, stimulates basement membrane extracellular matrix overproduction (fibronectin and type IV collagen), and directly upregulates vascular endothelial growth factor (VEGF).
The Hexosamine Pathway: Hyperglycaemic glycolytic flux shunts fructose-6-phosphate into the hexosamine biosynthetic pathway via glutamine:fructose-6-phosphate amidotransferase (GFAT). The end product, uridine diphosphate-N-acetylglucosamine ( UDP-GlcNAc \text{UDP-GlcNAc} UDP-GlcNAc ), leads to aberrant O-linked glycosylation of serine and threonine residues on transcription factors such as Sp1 \text{Sp1} Sp1 , driving the overexpression of plasminogen activator inhibitor-1 ( PAI-1 \text{PAI-1} PAI-1 ) and transforming growth factor-beta ( TGF- β \text{TGF-}\beta TGF- β ).
- Cellular and Structural Microvascular Pathology
- 1. Selective Pericyte Apoptosis ("Pericyte Ghosts")
Retinal capillaries are unique in exhibiting an intimate 1:1 ratio between pericytes and vascular endothelial cells , compared to a 10:1 or 20:1 ratio in other systemic vascular beds. Pericytes envelop the endothelial tube, providing structural tone, inhibiting uncontrolled endothelial proliferation via platelet-derived growth factor receptor-beta ( PDGFR- β \text{PDGFR-}\beta PDGFR- β ) signalling, and maintaining tight junction integrity. In diabetes, pericytes selectively undergo programmed cell death (apoptosis) mediated by sorbitol accumulation, oxidative stress, and p38 MAPK \text{p38 MAPK} p38 MAPK activation. The histological hallmark is the appearance of "pericyte ghosts" —empty pocket-like outpouchings in the capillary basement membrane. Loss of pericytic mechanical restraint leads to focal outpouchings of the capillary wall: microaneurysms .
2. Capillary Basement Membrane Thickening
Endothelial cells and residual pericytes synthesize excessive amounts of collagen IV, laminin, and fibronectin. Although the capillary basement membrane becomes markedly thickened, it is biochemically defective, brittle, and structurally disorganized, impeding normal nutrient exchange and gas diffusion.
3. Inner Blood-Retinal Barrier (BRB) Breakdown
The inner BRB is formed by non-fenestrated retinal capillary endothelial cells interconnected by specialized tight junctions (zonula occludens-1 [ ZO-1 \text{ZO-1} ZO-1 ], occludin, and claudin-5). PKC activation, elevated VEGF-A, and pro-inflammatory cytokines trigger phosphorylation, ubiquitination, and endocytosis of these junctional proteins. The consequent breakdown of the inner BRB permits transudation of fluid, plasma proteins, and lipoproteins into the neurosensory retina, culminating in diabetic macular oedema (DMO) and hard exudate formation in the outer plexiform layer (layer of Henle).
4. Capillary Non-Perfusion & Angiogenesis
Persistent endothelial cell apoptosis, luminal narrowing from basement membrane expansion, and retinal leukostasis (stiff, non-deformable neutrophils adhering to intercellular adhesion molecule-1 [ ICAM-1 \text{ICAM-1} ICAM-1 ]) trigger focal microthrombosis and capillary closure. Progressive capillary non-perfusion deprives the inner retinal layers of oxygen. Retinal ischaemia stabilizes the transcription factor Hypoxia-Inducible Factor 1-alpha ( HIF-1 α \text{HIF-1}\alpha HIF-1 α ) , preventing its prolyl-hydroxylation and proteasomal degradation. Accumulated HIF-1 α \text{HIF-1}\alpha HIF-1 α heterodimerizes with HIF-1 β \text{HIF-1}\beta HIF-1 β , translocates to the nucleus, and drives massive transcriptional upregulation of angiogenic factors, predominantly Vascular Endothelial Growth Factor-A (VEGF-A) , specifically the diffusible VEGF 165 \text{VEGF}_{165} VEGF 165 isoform , as well as angiopoietin-2 and stromal cell-derived factor-1 (SDF-1).
Standardized ETDRS Classification of Diabetic Retinopathy
The Early Treatment Diabetic Retinopathy Study (ETDRS) established the internationally accepted grading scheme for diabetic retinopathy, categorizing disease based on stereoscopic fundus photography and fluorescein angiography.
Non-Proliferative Diabetic Retinopathy (NPDR)
NPDR is characterized by intraretinal vascular lesions without the development of extraretinal neovascularisation breaching the internal limiting membrane (ILM):
Mild NPDR: At least one microaneurysm is present; no other diabetic retinal lesions satisfy the criteria for moderate or severe NPDR.
Moderate NPDR: Characterized by microaneurysms accompanied by intraretinal blot haemorrhages, hard exudates (lipid-rich deposits situated in the outer plexiform layer), or cotton-wool spots (fluffy white axoplasmic accumulations in the nerve fibre layer secondary to terminal precapillary arteriolar occlusion). The changes are more extensive than mild NPDR, but fall short of the severe NPDR threshold.
Severe NPDR (The 4:2:1 Rule): Severe NPDR indicates critical retinal ischaemia and represents a crucial prognostic watershed. It is formally diagnosed when a fundus exhibits any one of the three criteria comprising the validated ETDRS 4:2:1 Rule :
"4" Quadrants: Definite, severe intraretinal haemorrhages and microaneurysms in all four quadrants (ETDRS standard photograph 2A);
"2" Quadrants: Definite venous beading (segmental constriction and tortuous dilatation of retinal venules) in two or more quadrants ;
"1" Quadrant: Prominent intraretinal microvascular abnormalities (IRMA) in one or more quadrants (ETDRS standard photograph 8A).
Important
Prognostic Significance of the 4:2:1 Rule:
Meeting one criterion of the 4:2:1 rule designates Severe NPDR , carrying an approximate 50% risk of progressing to PDR within 1 year and a 15% risk of developing high-risk PDR.
Meeting two or more criteria of the 4:2:1 rule designates Very Severe NPDR , conferring an alarming 75% risk of progressing to PDR within 1 year .
Distinguishing IRMA from Retinal Neovascularisation (NVE)
Differentiating intraretinal microvascular abnormalities (IRMA) from true neovascularisation elsewhere (NVE) is a classical EBOD examination milestone:
Clinical & Angiographic Feature Intraretinal Microvascular Abnormalities (IRMA) Retinal Neovascularisation (NVE)
Anatomical Depth Confined strictly within the neurosensory retina (intraretinal) Breaches the internal limiting membrane (ILM); grows into vitreoretinal interface
Morphological Architecture Broad, irregular, dilated, non-tapering shunt collateral vessels Fine, delicate, lace-like, arborizing fronds of fragile new vessels
Relationship to Ischaemic Retina Runs within zones of capillary non-perfusion Typically arises at the boundary bordering perfused and non-perfused retina
Early Fluorescein Angiography Well-defined vessel outlines without early profuse dye leak Early hyperfluorescence from rapid dye transit through primitive endothelia
Late Fluorescein Angiography Minimal or mild focal staining; crisp margins preserved Massive, diffuse hyperfluorescent dye leakage obscuring vessel architecture